SU

229.05

+0.9%↑

BAS

52.38

-0.87%↓

REP

24.66

+1.73%↑

AM

318.8

+1.34%↑

EXE.US

109.72

-1.54%↓

SU

229.05

+0.9%↑

BAS

52.38

-0.87%↓

REP

24.66

+1.73%↑

AM

318.8

+1.34%↑

EXE.US

109.72

-1.54%↓

SU

229.05

+0.9%↑

BAS

52.38

-0.87%↓

REP

24.66

+1.73%↑

AM

318.8

+1.34%↑

EXE.US

109.72

-1.54%↓

SU

229.05

+0.9%↑

BAS

52.38

-0.87%↓

REP

24.66

+1.73%↑

AM

318.8

+1.34%↑

EXE.US

109.72

-1.54%↓

SU

229.05

+0.9%↑

BAS

52.38

-0.87%↓

REP

24.66

+1.73%↑

AM

318.8

+1.34%↑

EXE.US

109.72

-1.54%↓

Search

Eurofins Scientific SE

Geschlossen

62.48 -0.32

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

62.1

Max

62.98

Schlüsselkennzahlen

By Trading Economics

Einkommen

105M

228M

Verkäufe

1.9B

3.7B

KGV

Branchendurchschnitt

23.828

69.273

Dividendenrendite

1.18

Gewinnspanne

6.2

Angestellte

65,694

EBITDA

285M

693M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+18.28% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

1.18%

3.43%

Nächstes Ergebnis

1. Apr. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.8B

11B

Vorheriger Eröffnungskurs

62.8

Vorheriger Schlusskurs

62.48

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

Eurofins Scientific SE Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

31. März 2026, 23:31 UTC

Heiße Aktien

Stocks to Watch: Nike, RH, NCino

31. März 2026, 22:35 UTC

Ergebnisse

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1. Apr. 2026, 00:00 UTC

Akquisitionen, Fusionen, Übernahmen

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31. März 2026, 23:50 UTC

Akquisitionen, Fusionen, Übernahmen

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31. März 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31. März 2026, 23:33 UTC

Market Talk
Wichtige Nachrichtenereignisse

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31. März 2026, 23:21 UTC

Ergebnisse

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31. März 2026, 23:14 UTC

Market Talk
Ergebnisse

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31. März 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31. März 2026, 22:36 UTC

Ergebnisse

China Vanke 2025 Loss Widens >000002.SZ

31. März 2026, 22:36 UTC

Ergebnisse

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31. März 2026, 22:36 UTC

Ergebnisse

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31. März 2026, 22:36 UTC

Ergebnisse

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31. März 2026, 22:36 UTC

Ergebnisse

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31. März 2026, 21:46 UTC

Akquisitionen, Fusionen, Übernahmen

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31. März 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31. März 2026, 21:35 UTC

Ergebnisse

Nike Expects China Sales Down 20% in 4Q, CFO Says

31. März 2026, 21:35 UTC

Ergebnisse

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31. März 2026, 21:35 UTC

Ergebnisse

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31. März 2026, 21:33 UTC

Akquisitionen, Fusionen, Übernahmen

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31. März 2026, 21:33 UTC

Ergebnisse

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31. März 2026, 21:32 UTC

Ergebnisse

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31. März 2026, 21:28 UTC

Ergebnisse

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31. März 2026, 21:26 UTC

Ergebnisse

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31. März 2026, 21:25 UTC

Ergebnisse

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31. März 2026, 21:24 UTC

Market Talk
Ergebnisse

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31. März 2026, 21:22 UTC

Ergebnisse

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31. März 2026, 21:22 UTC

Ergebnisse

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31. März 2026, 21:21 UTC

Ergebnisse

Nike's Digital Channel Still Too Promotional, CFO Says

31. März 2026, 21:20 UTC

Ergebnisse

Nike CEO: Converse Remains Important to Portfolio

Peer-Vergleich

Kursveränderung

Eurofins Scientific SE Prognose

Kursziel

By TipRanks

18.28% Vorteil

12-Monats-Prognose

Durchschnitt 73.43 EUR  18.28%

Hoch 81 EUR

Tief 64 EUR

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Eurofins Scientific SE – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

4 ratings

2

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

54.22 / 56.82Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Eurofins Scientific SE

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of various analytical methods and tests to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, healthcare and cosmetics, and food supplements; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include sustainability, expert services and regulatory, consumer research and sensory evaluation, audits, testing, certifications and approvals, inspections, and training courses for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; food irradiation and labelling, heavy metals, carbohydrates, radioactivity, nutritional analysis, microbiolody, and testing for persistent organic pollutants, veterinary drug residue, dioxins and organic contaminants, pesticides, mycotoxins, and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and other services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
help-icon Live chat